Edison Group’s Edison Open House: Global Healthcare 2022 was a three-day event, in association with London Stock Exchange, global law firm Taylor Wessing and OpenExchange, which took place from January 25-27, focusing on 33 companies. Content is now available to stream.
Content is now available to stream on Edison’s website and OpenExchange.tv. Attendance is free and anyone wanting to attend can sign up here at www.edisongroup.com/edison-open-house-global-healthcare-2022/.
Day one featured businesses within pharmaceuticals and drug discovery, day two focused on businesses adopting new approaches to hard-to-solve problems, while AI & technology were covered on day three.
‘Fireside chats‘ with CXOs were hosted by Vivienne Parry MBE, the BBC broadcaster, science author and journalist. The aim was to reveal the investment cases of listed healthcare businesses in a way that makes the stocks accessible to all investors.
Separate panels saw opinion formers providing insight into the most important trends and advances predicted for 2022, the outlook for healthcare equity financing and the hot topics in biopharma partnering. Meanwhile ‘The Open 100’ offered ten TED-style ten-minute talks from handpicked CEOs.
According to Rachel Carroll, Edison’s US President and Managing Partner: “With record investment flows over the last couple years and a glut of new issuance, it has never been more important for healthcare entrepreneurs to establish mindshare and intelligently target the broadest potential pool of investment capital. We appreciate the momentous support of our virtual series as we look forward to a busy calendar of events with clients and partners in 2022.”
Ross McNaughton at Taylor Wessing said: “I can’t recall a time when there has been more interest or opportunity in the healthcare sector, or when there has been as many dimensions for companies and investors to take into consideration. As the pandemic continues to shine a light on the sector generally and as technological advances enabling both early diagnostics and personalised medicine continue apace, opportunities remain rife. Shifts in government policy, whether pricing or regulation of new products or otherwise, can have sudden and long-lasting impact upon the business model of entire sub-sectors. All of this means companies and their investors need to be ever more savvy about their business models and how they demonstrate their understanding of how to make use of market complexity ultimately to drive profitable revenue and growth. As a leading law firm in this space, we are delighted to be supporting this key stage conference once again, which will touch upon all of these topics and offer companies and investors the opportunity further hone their approach for the year to come.”